Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "Paris"

135 News Found

Yokogawa invests in glycan production company GlyTech
Biotech | January 04, 2022

Yokogawa invests in glycan production company GlyTech

Partnering to build biosynthesis processes and a pharmaceutical production platform


Biological E gets nod to study Corbevax as a booster dose
News | December 30, 2021

Biological E gets nod to study Corbevax as a booster dose

The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions


Biogen and TheraPanacea collaborate to advance digital health in neuroscience
Biotech | December 15, 2021

Biogen and TheraPanacea collaborate to advance digital health in neuroscience

Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology


Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials
Biotech | December 10, 2021

Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials

Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants


Covishield effectiveness during the second wave at 63 per cent
Public Health | November 30, 2021

Covishield effectiveness during the second wave at 63 per cent

Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent


Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22
News | November 11, 2021

Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22

Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021


Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
News | November 10, 2021

Marksons Pharma PAT slips to Rs 46.28 in Q2FY22

Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021


Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
News | November 10, 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021


Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively
Biotech | November 09, 2021

Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively

Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma


Divis Labs PAT at Rs 606.46 cr. in Q2FY22
News | November 08, 2021

Divis Labs PAT at Rs 606.46 cr. in Q2FY22

Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.